A new clinical cohort
WALTHAM, Mass.—Syndax Pharmaceuticals Inc. has expanded ENCORE 601/KEYNOTE 142, its Phase 2 clinical collaboration with a subsidiary of Merck & Co. (known as MSD outside the United States and Canada), to also include a patient population with microsatellite stable colorectal cancer. The trial is seeking to assess the safety, tolerability and efficacy of Syndax’s entinostat and Merck’s Keytruda as a combination therapy.
“Microsatellite stable colorectal cancers comprise approximately 85 percent of colorectal cancers, have limited treatment options once the disease advances and have been unresponsive to anti-PD-1 monotherapy,” said Dr. Briggs W. Morrison, CEO of Syndax. “This expansion of ENCORE 601/KEYNOTE 142 is based in part on the previously communicated clinical responses we observed for the entinostat-KEYTRUDA combination in advanced melanoma patients that had progressed on prior anti-PD-1 therapy.”